Camrelizumab Plus Chemo May Be New Presurgical Option in Breast Cancer Subset By Kristi Rosa December 16th 2024 Tecentriq Regimen Misses End Goal in Triple-Negative Breast Cancer By Jason Broderick December 14th 2024 HER3-DXd With or Without Femara Effective for Some With High-Risk Breast Cance...
Switching Chemo Regimen After Cycle 1 Not Beneficial in Metastatic Breast CancerBryant Furlow
performed CEA of breast cancer chemotherapy, comparing anthracycline-based regimens to non-anthracycline-based regimens. They found the anthracycline-based regimen to have 12.05 QALY with total treatment cost of $119,055 and the non-anthracycline-based regimen to have 9.56 QALY with total treatment ...
Targeting neddylation and sumoylation in chemoresistant triple negative breast cancer Reid T. Powell, Amanda L. Rinkenbaugh, Lei Guo, Shirong Cai, Jiansu Shao, Xinhui Zhou, Xiaomei Zhang, Sabrina Jeter-Jones, Chunxiao Fu, Yuan Qi, Faiza Baameur Hancock, Jason B. White, ...
Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors Article Open access 16 June 2020 XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients Article Open...
For example, in high-risk HR+/HER2- breast cancer patients, anthracyclines have traditionally been a component of the chemotherapy regimen. However, the joint analysis of the ABC trials showed that there is no benefit from the addition of anthracycline for lymph node-negative patients with HR+/...
Meaning In women with hormone receptor–positive, ERBB2-negative, axillary node–negative breast cancer, and a high 21-gene recurrence score, a higher proportion were free from distant recurrence when treated with chemoendocrine therapy than expected with endocrine therapy alone. Abstract Importance A...
The gene expression profiles of the M and MSL subtypes overlap with that of chemoresistant metaplastic breast cancer and display the up-regulation of genes involved in epithelial–mesenchymal transition, cell motility, extracellular matrix remodeling, and cellular differentiation. Unlike the M subtype, ...
Merck unveils data for Keytruda in triple-negative breast cancer, threatening Roche’s Tecentriq, but faces its own challenge from BMS in non-small cell lung cancer
The interpretation was limited by a lack of power.Through the use of nomograms, our study demonstrates that PABC is as chemosensitive as non-PABC and suggests that taxanes should be part of the NACT regimen for PABC. Further studies are warranted to increase the power of the presented ...